Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Shi, Gao-Na; Zhang, Chuang-Nian; Xu, Rong; Niu, Jin-Feng; Song, Hui-Juan; Zhang, Xiu-Yuan; Wang, Wei-Wei; Wang, Yan-Ming; Li, Chen; Wei, Xiao-Qing; Kong, De-Ling (2017)
Publisher: Elsevier
Languages: English
Types: Article
Subjects: RK

Classified by OpenAIRE into

mesheuropmc: nervous system diseases, technology, industry, and agriculture, therapeutics, health care economics and organizations
Whole tumor cell lysates (TCL) have been implemented as tumor antigens for cancer vaccine development, although clinical outcomes of TCL-based antitumor immunotherapy remain unsatisfactory. In order to improve the efficacy of TCL-based vaccines, biomaterials have been employed to enhance antigen delivery and presentation. Here, we have developed chitosan nanoparticles (CTS NPs) with surface mannose (Man) moieties for specific dendritic cells (DCs) targeting (Man-CTS NPs). The Man-CTS NPs were then loaded with TCL generated from B16 melanoma cells (Man-CTS-TCL NPs) for in vitro and in vivo assessment. Potency of the Man-CTS-TCL NPs as cancer vaccine was also assessed in vivo by immunization of mice with Man-CTS-TCL NPs followed by re-challenge with B16 melanoma cell inoculation. We have shown here that Man-CTS-TCL NPs promote bone marrow-derived dendritic cells (BMDCs) maturation and antigen presentation in vitro. In vivo evaluation further demonstrated that the Man-CTS-TCL NPs were readily taken up by endogenous DCs within the draining lymph node (DLN) following subcutaneous administration accompanied by increasing in serum IFN-γ and IL-4 levels. Tumor growth was also significantly delayed in mice primed with Man-CTS-TCL NPs vaccine, attributable at least in part to cytotoxic T lymphocytes response. Moreover, Man-CTS-TCL NPs vaccine also exhibited therapeutic effects in mice with melanoma. Thus, we report here the Man-CTS-TCL NPs as effective anti-tumor vaccine for cancer immunotherapy.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • [1] S.B. Coffelt, K.E. de Visser, Immune-mediated mechanisms influencing the efficacy of anticancer therapies, Trends Immunol. 36 (2015) 198-216.
    • [2] A.S. Cheung, D.J. Mooney, Engineered materials for cancer immunotherapy, Nano today 10 (2015) 511-531.
    • [3] A.Milani, D. Sangiolo, F. Montemurro, M. Aglietta, G. Valabrega, Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives, Ann. Oncol. 24 (2013) mdt133.
    • [4] K. Palucka, J. Banchereau, Dendritic-cell-based therapeutic cancer vaccines, Immunity 39 (2013) 38-48.
    • [5] I. Melero, G. Gaudernack, W. Gerritsen, C. Huber, G. Parmiani, S. Scholl, et al., Therapeutic vaccines for cancer: an overview of clinical trials, Nat. Rev. Clin. Oncol. 11 (2014) 509-524.
    • [6] J. Banchereau, A.K. Palucka, Dendritic cells as therapeutic vaccines against cancer, Nat. Rev. Immunol. 5 (2005) 296-306.
    • [7] S.T. Reddy, M.A. Swartz, J.A. Hubbell, Targeting dendritic cells with biomaterials: developing the next generation of vaccines, Trends Immunol. 27 (2006) 573-579.
    • [8] J. Banchereau, R.M. Steinman, Dendritic cells and the control of immunity, Nature 392 (1998) 245-252.
    • [9] F.O. Nestle, J. Banchereau, D. Hart, Dendritic cells: on the move from bench to bedside, Nat. Med. 7 (2001) 761-765.
    • [10] E. Segura, J.A. Villadangos, Antigen presentation by dendritic cells in vivo, Curr. Opin.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article